Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05045638 · ClinicalTrials.gov registry record · Phase 1

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

A Phase 1 study of Healthy Participants, sponsored by Amgen.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
1
Study location

NCT05045638 is a Phase 1 study of Healthy Participants that has completed, run by Amgen. The registered enrollment target is 13 participants, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05045638, a Phase 1 study of Healthy Participants, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.

Conditions Studied

Interventions

  • DRUG Sotorasib
  • DRUG Rosuvastatin

Study Locations (1)

Florida

  • Covance Clinical Research Unit - Daytona Beach - Daytona Beach

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2021-08-20
Est. Completion 2021-10-10
Phase Phase 1

Sponsor

Amgen

558 total trials

What the Registry Record Tells You About NCT05045638

The ClinicalTrials.gov registry entry for NCT05045638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 119 other Healthy Participants trials with a reported enrollment target (80% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Sotorasib is the first listed.

NCT05045638 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05045638 about?

NCT05045638 is a clinical study titled "Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants". A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.

What is the current status of trial NCT05045638?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-08-20. Estimated completion is 2021-10-10.

What conditions does trial NCT05045638 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT05045638?

The interventions under investigation include: Sotorasib (DRUG), Rosuvastatin (DRUG).

Who is sponsoring clinical trial NCT05045638?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05045638 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.